Artificial Intelligence-based Early Screening of Pancreatic Cancer and High Risk Tracing (ESPRIT-AI)

The study is being run by a team of dedicated physicians and researchers, led by Jin Gang, MD, Director of Department of general surgery of Shanghai Changhai Hospital. The trial will include individuals with new-onset diabetes (diagnosed within the past 3 year), familial pancreatic cancer, inherited syndromes associated with pancreatic cancer (including hereditary pancreatitis, familial atypical multiple mole and melanoma syndrome, hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, hereditary breast and ovarian cancer syndromes, etc), pancreatic cystic neoplasm (including IPMN, MCN) as well as chronic pancreatitis. Participants will undergo annual laboratory tests and high-resolution MRI/CT examinations of the pancreas. Any suspicious lesions will be further examined by endoscopic ultrasound (EUS). If pancreatic cancer or a pre-cancerous lesion is identified, the individual will be referred for surgery. We will also be collecting a blood sample from all participants for DNA isolation. Clinical data and biological specimens contained in this study may be used for a wide variety of future related studies to the cause, diagnosis, outcome and treatment of pancreatic cancer.

Inclusion criteria

• Subject is able and willing to provide informed consent and sign an informed consent form.
• Subject or authorized representative must be willing to complete a detailed questionnaire.
• Subject must meet one of the following criteria:

• New onset diabetes (diagnosed within the past 3 years)
• Familial pancreatic cancer
• Inherited syndromes associated with pancreatic cancer (including Hereditary pancreatitis, Familial atypical multiple mole and melanoma syndrome, Hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, Hereditary breast and ovarian cancer syndromes, etc)
• Pancreatic cystic neoplasm (including IPMN, MCN)
• Chronic pancreatitis

Exclusion criteria

• Subject has been diagnosed with pancreatic cancer or other malignant tumors in the last 5 years;
• Subject has any medical condition that contraindicates high-resolution MRI or CT;
• Subject cannot be followed up or is participating in other clinical trials.